296 related articles for article (PubMed ID: 21395525)
1. Conventional and novel approaches in generating and characterization of reactive intermediates from drugs/drug candidates.
Orhan H; Vermeulen NP
Curr Drug Metab; 2011 May; 12(4):383-94. PubMed ID: 21395525
[TBL] [Abstract][Full Text] [Related]
2. Practical approaches to resolving reactive metabolite liabilities in early discovery.
Dalvie D; Kalgutkar AS; Chen W
Drug Metab Rev; 2015 Feb; 47(1):56-70. PubMed ID: 25410913
[TBL] [Abstract][Full Text] [Related]
3. Detecting reactive drug metabolites for reducing the potential for drug toxicity.
Grillo MP
Expert Opin Drug Metab Toxicol; 2015; 11(8):1281-302. PubMed ID: 26005795
[TBL] [Abstract][Full Text] [Related]
4. Preclinical pharmacokinetics: an approach towards safer and efficacious drugs.
Singh SS
Curr Drug Metab; 2006 Feb; 7(2):165-82. PubMed ID: 16472106
[TBL] [Abstract][Full Text] [Related]
5. From toxic precursors to safe drugs. Mechanisms and relevance of idiosyncratic drug reactions.
Petersen KU
Arzneimittelforschung; 2002; 52(6):423-9. PubMed ID: 12109041
[TBL] [Abstract][Full Text] [Related]
6. Structural alerts, reactive metabolites, and protein covalent binding: how reliable are these attributes as predictors of drug toxicity?
Kalgutkar AS; Didiuk MT
Chem Biodivers; 2009 Nov; 6(11):2115-37. PubMed ID: 19937848
[TBL] [Abstract][Full Text] [Related]
7. Structural alert/reactive metabolite concept as applied in medicinal chemistry to mitigate the risk of idiosyncratic drug toxicity: a perspective based on the critical examination of trends in the top 200 drugs marketed in the United States.
Stepan AF; Walker DP; Bauman J; Price DA; Baillie TA; Kalgutkar AS; Aleo MD
Chem Res Toxicol; 2011 Sep; 24(9):1345-410. PubMed ID: 21702456
[TBL] [Abstract][Full Text] [Related]
8. Identification and characterization of reactive metabolites in natural products-driven drug discovery.
Njuguna NM; Masimirembwa C; Chibale K
J Nat Prod; 2012 Mar; 75(3):507-13. PubMed ID: 22296642
[TBL] [Abstract][Full Text] [Related]
9. Chemical metabolite synthesis and profiling: Mimicking in vivo biotransformation reactions.
Chhatrapati Bisen A; Nashik Sanap S; Agrawal S; Biswas A; Sankar Bhatta R
Bioorg Chem; 2023 Oct; 139():106722. PubMed ID: 37453238
[TBL] [Abstract][Full Text] [Related]
10. Drug bioactivation, covalent binding to target proteins and toxicity relevance.
Zhou S; Chan E; Duan W; Huang M; Chen YZ
Drug Metab Rev; 2005; 37(1):41-213. PubMed ID: 15747500
[TBL] [Abstract][Full Text] [Related]
11. Predicting toxicities of reactive metabolite-positive drug candidates.
Kalgutkar AS; Dalvie D
Annu Rev Pharmacol Toxicol; 2015; 55():35-54. PubMed ID: 25292426
[TBL] [Abstract][Full Text] [Related]
12. Characterization of cyanide-trapped methylated metabonates formed during reactive drug metabolite screening in vitro.
Rousu T; Tolonen A
Rapid Commun Mass Spectrom; 2011 May; 25(10):1382-90. PubMed ID: 21504003
[TBL] [Abstract][Full Text] [Related]
13. Extrahepatic targets and cellular reactivity of drug metabolites.
Orhan H
Curr Med Chem; 2015; 22(4):408-37. PubMed ID: 25174932
[TBL] [Abstract][Full Text] [Related]
14. Prediction of in vivo potential for metabolic activation of drugs into chemically reactive intermediate: correlation of in vitro and in vivo generation of reactive intermediates and in vitro glutathione conjugate formation in rats and humans.
Masubuchi N; Makino C; Murayama N
Chem Res Toxicol; 2007 Mar; 20(3):455-64. PubMed ID: 17309281
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of relative MS response factors of drug metabolites for semi-quantitative assessment of chemical liabilities in drug discovery.
Blanz J; Williams G; Dayer J; Délémonté T; Gertsch W; Ramstein P; Aichholz R; Trunzer M; Pearson D
J Mass Spectrom; 2017 Apr; 52(4):210-217. PubMed ID: 28152561
[TBL] [Abstract][Full Text] [Related]
16. Role of biotransformation in drug-induced toxicity: influence of intra- and inter-species differences in drug metabolism.
Baillie TA; Rettie AE
Drug Metab Pharmacokinet; 2011; 26(1):15-29. PubMed ID: 20978360
[TBL] [Abstract][Full Text] [Related]
17. Minimising the potential for metabolic activation in drug discovery.
Kalgutkar AS; Soglia JR
Expert Opin Drug Metab Toxicol; 2005 Jun; 1(1):91-142. PubMed ID: 16922655
[TBL] [Abstract][Full Text] [Related]
18. Managing the challenge of chemically reactive metabolites in drug development.
Park BK; Boobis A; Clarke S; Goldring CE; Jones D; Kenna JG; Lambert C; Laverty HG; Naisbitt DJ; Nelson S; Nicoll-Griffith DA; Obach RS; Routledge P; Smith DA; Tweedie DJ; Vermeulen N; Williams DP; Wilson ID; Baillie TA
Nat Rev Drug Discov; 2011 Apr; 10(4):292-306. PubMed ID: 21455238
[TBL] [Abstract][Full Text] [Related]
19. Metabolic bioactivation and drug-related adverse effects: current status and future directions from a pharmaceutical research perspective.
Tang W; Lu AY
Drug Metab Rev; 2010 May; 42(2):225-49. PubMed ID: 19939207
[TBL] [Abstract][Full Text] [Related]
20. Metabolic activation in drug-induced liver injury.
Leung L; Kalgutkar AS; Obach RS
Drug Metab Rev; 2012 Feb; 44(1):18-33. PubMed ID: 21939431
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
